# Parabilis Medicines (PBLS) — News

PBLS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/pbls/news

## Recent headlines

- [Parabilis Medicines - To disclose additional FAP data from phase 1/2 trial in Q1 2027](https://www.ainvest.com/news/parabilis-medicines-disclose-additional-fap-data-phase-1-2-trial-q1-2027-2610) — AInvest Wire, Oct 14, 2026
  Parabilis Medicines has announced plans to disclose additional FAP (Fibroblast Activation Protein) data from its ongoing phase 1/2 trial of zolucatetide (FOG-001) in the first quarter of 2027 . Zolucatetide is a Helicon peptide and the first direct inhibitor of the β-catenin: TCF interaction, a key…
- [Parabilis Medicines initiates dose-ranging clinical study of zolucatetide in familial adenomatous polyposis](https://www.ainvest.com/news/parabilis-medicines-initiates-dose-ranging-clinical-study-zolucatetide-familial-adenomatous-polyposis-2610) — AInvest Wire, Oct 14, 2026
- [Lycia Therapeutics Inc. files for IPO](https://www.ainvest.com/news/lycia-therapeutics-files-ipo-2610) — AInvest Wire, Oct 5, 2026
  Lycia Therapeutics Inc., a clinical-stage biotechnology company focused on the development of novel therapeutics for autoimmune, inflammatory, and allergic diseases, has recently made notable progress in its financing and development activities. The company, which has been backed by several…
- [HBM Healthcare Investments posts solid half-year result – expected profit of CHF 177 million](https://www.ainvest.com/news/hbm-healthcare-investments-posts-solid-year-result-expected-profit-chf-177-million-2610) — AInvest Wire, Oct 1, 2026
  HBM Healthcare Investments AG has reported a strong half-year performance, with an expected profit of CHF 177 million for the period. This result reflects continued growth and successful investment strategies across its portfolio companies. The firm has recently made significant investments in…
- [Regeneron exec says co eligible to receive $1 bln in potential milestone payment with the start of the first late-stage trial as part of the deal -Conf call](https://www.ainvest.com/news/regeneron-exec-eligible-receive-1-bln-potential-milestone-payment-start-late-stage-trial-part-deal-conf-call-2610) — AInvest Wire, Oct 1, 2026
  Regeneron Pharmaceuticals, Inc. (REGN) is positioned to receive up to $1 billion in potential milestone payments as part of its expanded collaboration with Sanofi, according to remarks made during a conference call. The companies announced the expansion of their longstanding antibody collaboration,…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).